Vector
Tularemia
search
Tularemia
, Francisella tularensis, Rabbit Fever
See Also
Tick-Borne Disease
Vector Borne Disease
Prevention of Tick-borne Infection
Tick Removal
Bioterrorism
Epidemiology
Peak onset in summer and fall
Endemic areas in United States (>50% of cases)
Arkansas
Missouri
Oklahoma
Pathophysiology
Francisella tularensis is causative organism
Small, aerobic
Gram-Negative Bacteria
Non-motile coccobacillus
Primarily found in the northern hemisphere
Carriers of F. tularensis
Mammals
Rabbits (most common vector, direct contact)
Wild rodents
Bobcats
Deer Fly
(Chrysops discalis)
Tick Vector
Amblyomma americanum (Lone star tick)
Dermacentor variabilis (Dog tick)
Transmission
No person to person transmission
Tick Bite
(accounts for 50% of U.S. cases)
Risk of exposure as
Biological Weapon
(inhalation of aerosolized
Biological Weapon
)
Highly infective
Infective Dose: Only 10 to 50 organisms need be inhaled for infection
Aerosolized F. tularensis decreases 90% within 30 to 60 minutes after exposure to
Ambien
t air at room
Temperature
Contaminated water ingestion or undercooked meat ingestion
Skin contact with infected animals (most common transmission)
Small outbreaks of inhalational Tularemia have occurred from contaminated grass or brush clippings
Disease pathogenesis
Bacteria
pentrates skin or mucosal surface
Spreads to regional
Lymph Node
s
Disease replicates and forms
Granuloma
s with central necrosis
Untreated disease disseminates rapidly
Incubation: 1 to 14 days
Symptoms
Constitutional (follows 3-5 day incubation)
Fever
and chills (all types)
Headache
Malaise or
Fatigue
Anorexia
Vomiting
Pharyngitis
Abdominal Pain
Diarrhea
Chest
discomfort
Myalgias
Type Specific Signs (divided over 6 classic types)
Ulceroglandular Type (most common)
Lymphadenopathy
as in Glandular type
Painful
Skin Ulcer
at site of vector bite and in region of
Lymphadenopathy
Glandular Type
Unlike ulceroglandular infection, there is no skin bite site, only
Lymphadenopathy
Localized, tender
Lymphadenopathy
Children: Cervical and occipital
Lymph Node
s
Adults: Inguinal
Lymph Node
s
Oculoglandular Type
Occurs when eye is splashed with contaminated water
Conjunctiva
involvement
Unilateral in 90% of cases
Early symptoms
Photophobia
Increased
Lacrimation
Later signs
Lid edema
Painful
Conjunctivitis
Sclera
l injection
Chemosis
Small yellow
Conjunctiva
l ulcers or
Papule
s
Lymphadenopathy
as in Glandular type above
Preauricular, Submandibular, and Cervical nodes
Pharyngeal Type
Associated with contaminated foodborne infection or waterborne infection
Exudative Pharyngitis
with severe
Sore Throat
Lymphadenopathy
as in Glandular Type
Cervical, pre-parotid and retropharyngeal nodes
Typhoidal Type
No significant
Lymphadenopathy
Profuse watery
Diarrhea
Bacteremia with
Hypotension
Pneumonic Type (most severe type)
Follows a 2 to 14 day
Incubation Period
Non-productive cough,
Headache
, rigors,
Pharyngitis
, myalgias,
Low Back Pain
Substernal and
Pleuritic Chest Pain
Infiltrates may be seen on
Chest XRay
Mortality approaches 60% with untreated severe variants
Distinguishing Features
Pulse-Temperature Dissociation
Pleural Effusion
s
Prominent
Hilar Adenopathy
Labs
Inflammatory markers normal
Erythrocyte Sedimentation Rate
(ESR) near normal
Complete Blood Count
White Blood Cell Count
near normal
Diagnosis
Rapid identification requires special testing facilities
Routine testing (cultures) will take weeks to grow the organism
Sputum
, tracheal aspirates, pharyngeal washings, gastric aspirates (rarely isolated from blood)
PCR
Direct fluorescent
Antibody
Immunohistochemical testing
Sputum Culture
or
Blood Culture
on
Cysteine
enriched media
Lab workers are at risk of transmission (warn of suspicion for Tularemia)
Tularemia
Serology
Confirms diagnosis at two weeks
Management
Isolation not required
No known person-to-person transmission
Risk of
Jarisch-Herxheimer Reaction
with treatment
Antibiotic
regimens are similar to those used in
Plague
Mild Disease (high relapse rate with these agents)
Doxycycline
(avoid under age 8 years)
Dose: 100 mg oral or IV twice daily for 14 to 21 days
Ciprofloxacin
(cartilage risk under age 18 years)
Dose: 400 mg IV q12 hours for 14 to 21 days
When improved convert to 750 mg oral twice daily
Alternatives in pregnancy:
Streptomycin
,
Chloramphenicol
Moderate to Severe Disease - Non-
Meningitis
cases (choose 1 agent)
Streptomycin
Dose: 15 mg/kg up to 1 g IM or IV every 12 hours for 10 to 14 days
Some protocols, allow dose to drop to 500 mg IV/IM daily for 5 days once affebrile
Do not use for
Meningitis
Gentamicin
or
Tobramycin
Adult: 5 mg/kg IM or IV every 24 hours for 10 to 14 days
Child: 2.5 mg/kg IM or IV every 8 hours for 10 to 14 days
Meningitis
Gentamicin
or
Tobramycin
(at dose above) AND
Chloramphenicol
50-100 mg/kg/day divided q6 hours IV
Prevention
Live Attenuated Vaccine
0.1 ml dose via scarification
Previously available
Vaccine
(to protect lab workers) is no longer available
Post-exposure Prophylaxis
(adult dosing below) after aerosol exposure
Continue for 14 days or length of exposure
Doxycycline
(over age 8 years)
Adults: 100 mg orally twice daily
Child: 2.2 mg/kg (max: 100 mg) orally every 12 hours (only if over age 8 years old)
Ciprofloxacin
Adult: 500 mg orally twice daily
Child: 15 mg/kg (max: 500 mg) orally twice daily (avoid under age 18 if possible, cartilage risk)
Tetracycline
Adults: 500 mg orally four times daily
Prevention
See
Prevention of Vector-borne Infection
Live Vaccine
if high risk of exposure
Handlers of rabbits and rodents (live or dead) should wear gloves
Prognosis
Mortality <2%
Mortality for untreated pneumonic type with virulent strain: 60%
Resources
CDC: Tularemia
http://www.cdc.gov/tularemia/
References
(2018) Sanford Guide, accessed IOS app 1/30/2020
Seeyave (2015) Crit Dec Emerg Med 29(5): 13-21
Charbonnet and Mace (2023) Crit Dec Emerg Med 37(4): 4-10
Dennis (2001) JAMA 285(21):2763-73 [PubMed]
Huntington (2016) Am Fam Physician 94(7): 551-7 [PubMed]
Maurin (2011) Clin Infect Dis 53(10): e133-41 +PMID:22002987 [PubMed]
Nigrovic (2008) Infect Dis Clin North Am 22(3): 489-504 +PMID:18755386 [PubMed]
Pace (2020) Am Fam Physician 101(9): 530-40 [PubMed]
Rathjen (2021) Am Fam Physician 104(4): 376-85 [PubMed]
Type your search phrase here